Improving Outcomes in FLT3-mutant AML: Crenolanib + Chemo | Thomas Cluzeau, MD, PhD

Improving Outcomes in FLT3-mutant AML: Crenolanib + Chemo | Thomas Cluzeau, MD, PhD

Highlights of Relapsed/Refractory Multiple Myeloma | Mohamad Mohty, MD, PhD

Highlights of Relapsed/Refractory Multiple Myeloma | Mohamad Mohty, MD, PhD

Highlights of Newly Diagnosed Multitple Myeloma | Mohamad Mohty, MD, PhD

Highlights of Newly Diagnosed Multitple Myeloma | Mohamad Mohty, MD, PhD

Can Linvoseltamab Be Safely Combined with Anti-CD38 Antibodies? | Meletios Dimopoulos, MD

Can Linvoseltamab Be Safely Combined with Anti-CD38 Antibodies? | Meletios Dimopoulos, MD

What I Learned at ASH as a Myeloma Patient: Personalized Care & Access | Valarie Traynham

What I Learned at ASH as a Myeloma Patient: Personalized Care & Access | Valarie Traynham

Defining Functional High-Risk Myeloma & Why Its Important | Barry Paul, MD & Todd Kennedy

Defining Functional High-Risk Myeloma & Why Its Important | Barry Paul, MD & Todd Kennedy

Join the Nutrivention 2 Study: Investigating a Plant Based Diet for MGUS or Smoldering Myeloma | Urvi Shah, MD

Join the Nutrivention 2 Study: Investigating a Plant Based Diet for MGUS or Smoldering Myeloma | Urvi Shah, MD

Highlights of Smoldering Multiple Myeloma from ASH25 | Mohamad Mohty, MD, PhD

Highlights of Smoldering Multiple Myeloma from ASH25 | Mohamad Mohty, MD, PhD

Long-term PFS updates on the CARTITUDE-4 Trial | Luciano Costa, MD

Long-term PFS updates on the CARTITUDE-4 Trial | Luciano Costa, MD

Daratumumab VS Lenalidomide maintenance therapy in Multiple Myeloma | Urvi Shah, MD

Daratumumab VS Lenalidomide maintenance therapy in Multiple Myeloma | Urvi Shah, MD

Does Diet Impact Treatment Response? Join NUTRIVENTION Study for Newly Diagnosed Myeloma | Urvi Shah, MD

Does Diet Impact Treatment Response? Join NUTRIVENTION Study for Newly Diagnosed Myeloma | Urvi Shah, MD